THER-09. IMPACT OF KRAS MUTATION STATUS ON THE EFFICACY OF IMMUNOTHERAPY IN LUNG CANCER BRAIN METASTASES

BACKGROUND: Immunotherapy is increasingly used in patients with non-small cell lung cancer brain metastases (NSCLCBM). KRAS mutations are associated with worse prognosis and there is no FDA approved targeted therapy. KRAS mutations are associated with increased expression of PD-L1. We evaluated the...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neurooncol Adv
Auteurs principaux: Lauko, Adam, Ali, Assad, Sagar, Soumya, Barnett, Addison, Li, Hong, Chao, Samuel, Pennell, Nathan, Stevens, Glen, Peereboom, David, Yu, Jennifer, Murphy, Erin, Angelov, Lilyana, Mohammadi, Alireza, Suh, John, Barnett, Gene, Ahluwalia, Manmeet
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2019
Sujets:
Abstracts
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7213262/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdz014.052
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires